Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress

Exclusion Criteria

• •1. In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
• •2. Patient has a do-not-resuscitate (DNR) or do-not-intubate (DNI) order in place
• •3. Patient has severe chronic obstructive pulmonary disease (COPD), chronic renal failure, or significant liver abnormality (e.g. cirrhosis, transplant, etc.).
• •4. Patient is on chronic immunosuppressive medication.
• •5. As a result of the medical review and screening investigation, the Principal Investigator considers the patient unfit for the study.
• •6. A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate).
• •7. Patient has known pregnancy or is currently breastfeeding.
• •8. Participation in another clinical trial (not including treatments for COVID-19 as approved by the FDA through expanded access or compassionate use).
• •9. Baseline QT prolongation.